Clinical and Serological Outcome of Genital Herpes Simplex Virus (HSV) Type 2 Inoculation following Oral HSV Type 1 Infection in Guinea-pigs
|
|
- Rafe Perkins
- 6 years ago
- Views:
Transcription
1 J. gen. Virol. (1989), 70, Printed in Great Britain 2365 Key words: HSV/genital disease~immune response Clinical and Serological Outcome of Genital Herpes Simplex Virus (HSV) Type 2 Inoculation following Oral HSV Type 1 Infection in Guinea-pigs By DAVID I. BERNSTEIN, 1. FRANCIS K. LEE, 2 GARY ECHLER 1 AND ANDRE J. NAHMIAS 2 1James N. Gamble Institute of Medical Research, 2141 Auburn Avenue, Cincinnati, Ohio and 2Division of Pediatric Infectious Disease, Emory University, Atlanta, Georgia 30322, U.S.A. (Accepted 8 May 1989) SUMMARY The clinical and serological outcome of genital herpes simplex virus type 2 (HSV-2) inoculation in animals previously orally infected with HSV type 1 was evaluated. A prior HSV-1 oral infection modified the genital HSV-2 infection so that only four of 18 (22~) animals were initially symptomatic although all but one animal shed HSV-2 from the cervicovaginal area for at least 5 days following inoculation. Three of four animals with symptomatic initial disease also developed recurrences, as did an additional six animals that did not manifest acute genital disease. Anti-glycoprotein gg-1 antibody was found in 17 of 18 animals with only an HSV-1 infection and antigg-2 antibody in all of nine animals with only an HSV-2 infection. Anti-gG-2 antibody was detected in eight of 17 animals with a prior HSV-1 infection following HSV-2 inoculation and one had an indeterminate response. Eight of these nine animals developed recurrent genital disease compared to one of eight that did not respond to gg-2 (P<0.006). Thus a prior oral HSV-1 infection modified both the initial presentation of HSV-2 infection and the HSV type-specific serological response. INTRODUCTION Genital herpes simplex virus type 2 (HSV-2) infection is one of the most commonly diagnosed sexually transmitted diseases. Patients can be divided into those with true primary infection and those with pre-existing HSV antibody, who have what is termed first episode, non-primary or initial infection (Nahmias et al., 1981 ; Bryson et al., 1983; Straus et al., 1985). Approximately 40 ~ of patients with their first clinically apparent episode of genital disease due to HSV-2 have pre-existing HSV antibody (Bryson et al., 1983; Reeves et al., 1981 ; Corey et al., 1983). These patients appear to have milder primary infection than those with true primary HSV-2 infections (Bryson et al., 1983 ; Corey et al., 1983; Whitley, 1985), although the proportion of patients who remain asymptomatic or develop such mild symptoms that they do not seek medical attention is unknown. A large proportion of HSV-2-infected patients are unaware that they have been infected (Mertz et al., 1985; Prober et al., 1988). Most if not all of these patients have HSV-2 latent in dorsal root ganglia; the virus could reactivate and cause recurrent symptomatic or asymptomatic disease (Mertz et al., 1985; Prober et al., D88, Mertz etal., 1988). it is possible that such patients are largely those who have pre-existing HSV-1 antibody at the time of exposure to HSV-2 and that the antibody modifies the genital disease to the extent that it is not recognized. It is also possible that in some cases a prior oral HSV-1 infection could provide complete protection against exposure to HSV-2. Detection of HSV type-specific antibody has been difficult because of the extensive crossreactivity that exists between HSV-I and HSV-2 (Spear, 1975; Eberle & Courtney, 1981; Bemstein et al., 1985). Recent methods have been based on the antibody response to typespecific HSV-1 glycoprotein G (gg-1) and HSV-2 glycoprotein G (gg-2) (Lee et al., 1985, 1986). The antibody response to gg-1 and gg-2 has proved reliable in diagnosing patients with SGM
2 2366 D. I. BERNSTEIN AND OTHERS documented infection to one or the other serotype (Lee et al., 1985, 1986; Ashley et al., 1988; Sullender et al., 1988). The identification of patients infected with both viruses is, however, most difficult (McClung et al., 1976; Nahmias et al., 1970; Plummer, 1973) and only limited data are available from them (Ashley et al., 1988). Thus, the sensitivity at which HSV-2 antibodies can be identified in patients with a prior HSV-1 infection is unknown and will be difficult to assess. We have therefore investigated the outcome of genital HSV-2 inoculation in guinea-pigs previously infected with HSV-1 orally. Vaginal inoculation of guinea-pigs with HSV-2 produces a disease pathophysiologically similar to human disease including symptomatic recurrences (Stanberry et al., 1982; Bernstein et al., 1986). We were thus able to determine the effects of prior oral HSV-1 infection on the clinical, virological and serological response of animals inoculated intravaginally with HSV-2. METHODS Animalinoculation. Thirty-one female Hartley guinea-pigs (Charles River Breeding Laboratory) weighing 300 to 350 g were used. To infect animals orally the upper lip was scarified with a 27-gauge needle or with a multiple puncture apparatus (Bignell) and then inoculated with 20 ~tl of medium containing 2 x 105 p.f.u, of HSV-1 strain Shealy (18 animals) (obtained originally from Dr Kurt Bubel, University of Cincinnati, Ohio, U.S.A.) or 2 x l0 s p.f.u. HSV-2 strain MS (four animals) (ATCC VR-540). Vaginal inoculation with 5 x 105 p.f.u, of HSV-2 strain MS was performed as previously described (Stanberry et al, 1982; Bernstein et al., 1986). In experiment 1, 12 animals were inoculated with HSV-2 6 months after oral infection (four with prior HSV-1 oral infections, four with prior oral HSV-2 infection and four controls, no prior oral infection). In experiment 2, 19 animals were inoculated 10 months after oral infection (14 with prior HSV-1 oral infection and five controls). Genital HSV-2 disease. Animals were examined daily for external skin lesions. The acute disease, during the defined period of days 0 to 14 (when all lesions had healed), was quantified on a scale of 0 to 4 as previously described (Stanberry et al., 1982). Recurrent disease was scored from day 15 until day 60 (Bernstein et al., 1986). Cervicovaginal HSV-2 cultures were obtained daily for the first 10 days after vaginal inoculation by insertion of a moistened calcium alginate swab into the vagina (Stanberry et al., 1982; Bernstein et al., 1986). Samples were frozen at - 70 C until virus was titrated by plaque assay in rabbit kidney cells (Bernstein et al., 1986). To compare the differences in mean viral titres we computed the area under the log10 virus titre-day curve (viral shedding curve) (Kern et al., 1978). Immunodot assay. Serotype-specific antibodies were identified by detection of antibody to gg-1 and gg-2 as described previously (Lee et al., 1985, 1986). Briefly, immunoaffinity column-purified gg-1 and gg-2 were diluted in Tris-buffered saline (TBS) ph 7.2, dotted onto nitrocellulose discs and placed into 96-well plates. After drying and blocking with 5% bovine serum albumin (BSA) in TBS (TBS-BSA) the coded test sera were diluted 1:50 in TBS-BSA and added to duplicate wells. Following overnight incubation the discs were washed and reblocked with TBS-BSA prior to the addition of goat anti-guinea-pig IgG-peroxidase conjugate (Sigma). After incubation for 1 h, the substrate 4-chloro-l-naphthol was added for 15 min. Discs were then rinsed with distilled water and read after overnight drying. The immunodot assay was interpreted by two observers without knowledge of the inoculation history. RESULTS Oral HSV-1 infection Following abrasion of the upper lip and HSV-1 inoculation, vesicular lesions were observed beginning on day 2 at the inoculation site with occasional satellite lesions noted by day 5 near the inoculation site and under the ipsilateral nares (Fig. 1). Lesions healed by days 7 to 9. The use of the multiple puncture apparatus resulted in more distinct vesicles. Genital HSV-2 infection Typical genital HSV-2 disease developed in all control animals from which HSV-2 was recovered (Fig. 2). Genital lesions peaked on day 6 or 7 and resolved by day 14. Urinary retention developed in all animals and hind limb paralysis was noted in 63 %. Prior oral infection with HSV-1 10 weeks or 6 months prior to genital inoculation reduced clinical disease~so that only three of 18 (17%) HSV-2 vaginally inoculated animals developed any genital e~ions and one other developed urinary retention without lesions. No other animal developed urinary
3 HSI,'-2 following oral HSI,'-I infection 2367 Fig. 1. Oral HSV-I infection of Hartley guinea-pigs 5 days after inoculation. (a) Animals were inoculated by abrading the upper lip with a 27-gauge needle prior to HSV-1 inoculation. (b) Animals were inoculated with the use of a multiple puncture apparatus. Arrowheads indicate HSV lesions \+ A T A\+ 1 i i zx--a~ Time after inoculation (days) Fig. 2. The clinical course of external genital skin disease in female guinea-pigs inoculated with HSV-2 after a prior oral HSV-1 infection (11) or in controls with no prior HSV infection (z~x). Values are expressed as mean lesion score + s.d. retention or hind limb paralysis. In experiment 1 (genital inoculation 6 months after oral infection) one of four animals with a prior oral HSV-1 infection developed a single genital lesion on day 13 (animal 4, Table 1). In experiment 2 (genital inoculation 10 weeks after oral HSV-1 infection) two of 14 animals developed single genital lesions on day 4 and 5 (animals 12 and 14). None of the four animals given HSV-2 orally 6 months prior to genital inoculation (animals 5 to 7 plus one animal not included in Table 1) developed any clinical genital disease. In experiment 1, no significant differences were noted in recovery of cervicovaginal HSV-2 from control (area under the viral shedding curve ) compared to animals with prior HSV-1 infection (area under the viral shedding curve ) although shedding was decreased from days 2 to 6 in HSV-l-infected animals (Fig. 3 a). Animals inoculated orally with HSV-2 6+months prior to vaginal challenge had an area under the viral shedding curve of compared to for control (P = 0-06, two-tailed Student's t-test) (Fig. 3b). In
4 2368 D. I. BERNSTEIN AND OTHERS Table 1. Antibody response to HSV-1 glycoprotein G and HSV-2 glycoprotein G in controls and animals previously infected orally Guinea-pig no. (experiment) Animals with prior HSV-1 oral infection Sera obtained after Sera obtained oral infection and before after HSV-2 genital inoculation genital inoculation * * Acute clinical Genital gg-1 gg-2 gg-1 gg-2 genital disease recurrence 1 (1)* (1) (1) (1) (2)t + - NDII ND (2) (2) I (2) (2) (2) (2) (2) (2) (2) (2) + - I (2) (2) (2) Animals with prior HSV-2 oral infection 5 (1) (1) (1) Control animals without prior oral HSV-1 or HSV-2 infection 8 (1) (1) (2) (2)~ (2) (2) (2) * Animals 1 to 9 were used in experiment 1 in which animals were infected with HSV-2 intravaginally 6 months after the oral infection. 1" Animals 10 to 28 were used in experiment 2 in which animals were inoculated with HSV-2 intravaginally 10 weeks after the HSV-I oral infection. :~ This animal did not shed HSV-2 after intravaginal HSV-2 inoculation and was not considered infected. Did not develop external lesions but did develop urinary retention. II ND, Not determined. I, Indeterminate, a discrepancy between observers. experiment 2, animals with a prior HSV-1 oral infection shed significantly less virus than control animals (area under the viral shedding curve of compared to ; P < ) (Fig. 3 c). If all animals given HSV-1 orally are compared to controls, significantly less virus was shed on days 3 to 10 (P < 0.05 on each day) and the area under the viral shedding curve was reduced from to (P < ) (Fig. 4). All but one HSV-1 orally infected animal shed HSV-2 for at least 5 days after genital inoculation. All control animals that shed HSV-2 developed recurrent genital lesions and nine of 18 animals with a prior HSV-1 oral infection developed a clinically obvious recurrent lesion. This included three of the four with acute symptoms and six that had not developed detectable symptoms after the acute disease. HSV-2 was recovered from four of six recurrent lesions evaluated. None of the three animals (one died during a bleed) with a prior HSV-2 oral infection developed recurrences.
5 HSV-2 following oral HSV-1 infection /i i i i i i i i I I iii i I i I i I i I /I I I I I I i i I I/ ~-i~,.;~ ~ ~ 6 ~ ~ ia) 4 _/ _. (b) ~ t. _ (c)_ Time after inoculation (days) Fig. 3. The course of cervicovaginal HSV-2 replication in animals after intravaginal HSV-2 inoculation. In experiment l, animals were inoculated with HSV-2 6 months after either oral HSV-1 infection (a) or oral HSV-2 infection (b). In experiment 2, animals were inoculated with HSV-2 10 weeks after oral HSV-1 infection (c). Replication was measured by plaque titration of vaginal swab samples and expressed as the geometric mean titres + S.D. for prior oral infection (ll) and for controls with no prior infection (LX). 8 I I I I I I I i I I o~ O.o 4 * -- ;> 2 ** 0-" I I I I J 1 T ~ i 9 mm 10 Time after inoculation (days) Fig. 4. The course of cervicovaginal HSV-2 replication after intravaginal HSV-2 inoculation in all animals with a prior oral HSV-1 infection (n) or controls with no prior HSV infection (z~). Replication was measured by plaque titration of vaginal swab samples and expressed as the geometric mean titre + S.D. * indicates significant (/><0-05) difference between groups; ** indicates difference was significant at the P < 0,005 level. Area refers to area under the curve (see Methods). Antibody response Sera were available from all but three animals, two controls from experiment 1 and one animal with a prior HSV-2 oral infection (Table 1). Three sera obtained before either oral or genital HSV infection did not react to gg-1 or gg-2 (data not shown). After HSV-1 oral infection, 17 of 18 animals responded to gg-1 and none to gg-2. After HSV-2 genital inoculation all control animals evaluated (no prior HSV infection) except one (which did not shed HSV-2) responded to gg-2 but not to gg-1. Eight of 17 animals with a prior HSV-1 infection responded to gg-2 at 30 to 40 days after HSV-2 genital inoculation and one had an indeterminate response. Eight of these nine developed recurrent genital disease compared to one of eight that did not respond to gg-2 (P < by Fisher's exact test). The other animal with anti-gg-2 antibody had developed a single lesion on day 13. The one HSV-1 orally infected animal without detectable anti-gg-1 antibody (Table 1, animal 1) had gg-1 antibody when re-evaluated after HSV-2 inoculation and one gg-1-positive animal (Table 1, animal 4) lost detectable anti-gg-1 antibody when re-evaluated after HSV-2 inoculation (6 months after HSV-1 oral infection). One animal (Table 1, animal 5; oral and genital HSV-2 infection) initially responded to gg-2 then responded only to gg-1 at 2 weeks after HSV-2 inoculation (data not shown) and then to both gg-1 and gg-2. No correlation could be found between the magnitude of vaginal virus replication and either the detection of anti-gg-2 antibody or recurrent disease. The area under the log10 vaginal viral
6 2370 D. I. BERNSTEIN AND OTHERS shedding per day curve of animals with a previous oral HSV-1 infection that did not respond to gg-2 ( ) was similar to that of animals that did respond ( ). Similarly, the area under the log10 vaginal virus per day curve of animals with a prior oral infection that developed recurrent disease ( ) was not significantly different from those which did not develop recurrent disease ( ). DISCUSSION Although a prior HSV-1 infection can modify human genital HSV-2 disease (Corey et al., 1983) the extent to which it alters the clinical and serological outcome is undefined because patients who do not develop clinical disease would not seek medical attention. Patients who develop a latent infection after asymptomatic primary disease may later develop clinically obvious disease (Bernstein et al., 1984) or asymptomatically shed virus and expose either their sexual partner (Rooney et al, 1986) or newborns (Prober et al, 1988) to HSV. Prospective studies under way will help define the role of prior HSV-1 infection in genital HSV-2 disease. In this animal model, guinea-pigs with a prior oral HSV-1 infection developed milder initial disease with reduced but not absent cervicovaginal shedding when challenged intravaginally with HSV-2. It appeared that shortening the interval between the oral infection and genital inoculation or the use of HSV-2 to infect animals orally may be important factors in limiting genital HSV-2 replication although the number of animals on which these data were based was small. Future experiments will investigate both of these parameters further. Three of four animals with a prior oral HSV-1 infection and initial symptomatic genital infection developed recurrences and, more interestingly, an additional six animals that had not developed symptomatic disease initially, did manifest symptomatic recurrent genital disease. Thus, a total of l0 of 18 (56~) animals with a prior oral HSV-1 infection eventually developed symptomatic genital HSV-2 disease after genital inoculation. These experiments support our observation that patients presenting with their first clinical episode of genital herpes may not be experiencing a primary infection but a recurrence of a previously asymptomatic infection (Bernstein et al., 1984). An additional eight animals with a prior oral HSV-1 infection did not develop clinical disease or seroconvert to gg-2 but demonstrated local genital HSV-2 replication. Extrapolation of these results to human disease suggests that a prior oral infection would predispose a patient to develop asymptomatic or mild disease after exposure to HSV-2 and these patients may indeed make up a significant proportion who are unaware of their genital HSV-2 infection. The immunodot assay for HSV serotype-specific antibody was shown to be reliable. AntigG-1 antibody was detected in 17 of 18 acutely HSV-1-infected animals and was detected in the other initially gg-l-seronegative animal on repeat examination after the HSV-2 inoculation. Only one animal lost detectable anti-gg-1 antibody at 6 months after HSV-1 infection. AntigG-2 antibody was detected in all HSV-2-infected control animals. Before dual infections, no anti-gg-2 antibodies were detected although one animal with an HSV-2 oral infection developed anti-gg-1 antibody. It is possible but unlikely that this animal acquired an HSV-1 infection from animals in adjacent cages. In 17 animals with a prior HSV-1 infection, anti-gg-2 antibody was detected in eight animals after HSV-2 genital inoculation and one animal had an indeterminate response. Anti-gG-2 antibody was detected in eight of 10 animals that developed either acute or recurrent disease and an indeterminate response was observed in a ninth animal. Since it is not known whether the other animals developed a latent infection or recurrent asymptomatic shedding, the sensitivity of this assay cannot be stated with certainty. Nevertheless, it did identify seven of nine animals that developed a genital recurrence including five of six initially asymptomatic animals. Future studies will address the question of latency in asymptomatic animals. In summary, a prior HSV-1 oral infection modified genital HSV-2 infection so that only 22 were initially symptomatic although 56 ~o eventually developed clinical symptoms. It is not clear whether the remaining animals were latently infected although all but one shed virus from the
7 HSV-2 following oral HSV-1 infection 2371 cervicovaginal area for at least 5 days. Immunodot analysis of anti-gg-1 and -gg-2 antibody was specific and identified dual infection in eight of 10 animals with acute or recurrent HSV-2 disease. This work was supported by grant AI23482 and AI19554 from the National Institute of Allergy and Infectious Disease. REFERENCES ASHLEY, R. L., MILITONI, L, LEE, F., NAHMIAS, A. & COREY, L. (1988). Comparison of Western blot (immunoblot) and glycoprotein G-specific immunoblot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. Journal of Clinical Microbiology 26, BERNSTEIN, D. I., LOVE'IT, M. & BRYSON, Y. J. (1984). Serologic analysis of first episode non-primary genital HSV infection: presence of HSV-2 antibody in acute sera. American Journal of Medicine 77, BERNSTEIN, D. I., BRYSON, Y. J. & LOVE1"r, M. A. (1985). Antibody response to type-common and type-unique epitopes of herpes simplex virus polypeptides. Journal of Medical Virology 15, BERNSTEIN, D. I., STANBERRY, L. R., HARRISON, C. l., KAPPES, J. C. d~ MYERS, M. G. (1986). Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir. Journal of General Virology 67, BRYSON, Y. J., DILLON, M., LOVETT, M., ACUNA, G., TAYLOR, S., CHERRY, L D., JOHNSON, B. L., WIESMEIER, E., GROWDON, W., CREAGH-KIRK, T. & KEENEY, R. (1983). Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. New England Journal of Medicine 308, COREY, L., ADAMS, H. G., BROWN, Z. A. & HOLMES, K. K. (1983). Genital herpes simplex virus infections: clinical manifestations, course and complications. Annals of Internal Medicine 98, EBERLE, R. & COURTNEY, R. J. (1981). Assay of type-specific and type-common antibodies to herpes simplex virus types 1 and 2 in human sera. Infection and Immunity 31, KERN, E. R., GLASGOW, L. A., OVERALL, J. C., RENO, J. M. & BOEZI, A. (1978). Treatment of experimental herpesvirus infection with phosphonoformate and some comparisons with phosphonacetates. Antimicrobial Agents and Chemotherapy 14, LEE, F. K., COLEMAN, M., PEREIRA, L., BAILEY, P. D., TATSUNO, M. & NAHMIAS, A. J. (1985). Detection of herpes simplex virus type 2 specific antibody with glycoprotein G. Journal of Clinical Microbiology 22, LEE, F. K., PEREIRA, L., GRIFFIN, e., REID, E. & NAHMIAS, A. (1986). A novel glycoprotein for detection of herpes simplex virus type 1 specific antibodies. Journal of Virological Methods 14, McCLUNG, H., PRALEE, S. & PAWLS, W. E. (i976). Relative concentration in human sera of antibodies to crossreaction and specific antigens of herpes simplex virus types 1 and 2. American Journal of Epidemiology 104, MERTZ, G. J., SCHMIDT, O., JOURDEN, J. L., GUINAN, M. E., REMINGTON, M. L., FAHNLANDER, A., WINTER, C., HOLMES, g. K. & COREY, L. (1985). Frequency of acquisition of first episode genital herpes simplex virus from symptomatic and asymptomatic source contacts. Sexually Transmitted Diseases 12, MERTZ, G. J., COOMBS, R. W., ASHLEY, R., JOURDEN, J., REMINGTON, M., WINTER, C., FAHNLANDER, A., GUINAN, M., DUCEY, H. & COREY, L. (1988). Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. Journal of Infectious Diseases 157, NAHMIAS, A. J., JOSEY, W. E., NAIB, Z. M., LUCE, C. F. & DUFICEY, C. (1970). Antibodies to herpes virus hominis types 1 and 2 in humans. I. Patients with genital herpetic infections. American Journal of Epidemiology 91, NAHMtAS, A. J., DAN~',rE~GER, J., WlCKLIFFE, C. & MtrrnBR, ~. (1981). Clinical aspects of infection with herpes simplex viruses 1 and 2. In The Human Herpesviruses: An Interdisciplinary Perspective, pp Edited by A. J. Nahmias. New York: Elsevier. PLUMMER, G. (1973). A review of the identification and titration of antibodies to herpes simplex viruses type 1 and 2 in human sera. Cancer Research 33, PROBER, C. G., HENSLEIGH, P. A., BOUCHER, F. D., YASAKAWA, L. I., AU, D. S. & ARVIN, A. M. (1988). Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus. New England Journal of Medicine 318, REEVES, W. C., COREY, L., ADAMS, H. G., VONTVER, L. A. & HOLMES, K. K. (1981). Risk of recurrence after first episodes of genital herpes. New England Journal of Medicine 305, ROONEY, J. F., FELSER, J. M., OSTROVE, I. M. & STRAUS, S. E. (1986). Acquisition of genital herpes from an asymptomatic sexual partner. New England Journal of Medicine 314, SPEAR, I,. G. (1975). Glycoproteins specified by herpes simplex virus type 1: their synthesis, processing and antigenic relatedness to HSV-2 glycoproteins. IARC Science Publications 14, STANBERRY, L. R., KERN, E. R., RICHARDS, J. T., ABBOTT, T. M. & OVERALL, J. C., JR (1982). Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent diseases. Journaloflnfectious Diseases 146, STRAUS, S. E;, ROONEY, J. F., SEVER, J. L., SEIDLIN, M., NUSINOFF-LEHRMAN, S. & CREMER, K. (1985). Herpes simplex virus infection: biology, treatment and prevention. Annals of Internal Medicine 103,
8 2372 D. I. BERNSTEIN AND OTHERS SULLENDER, W. M., YASUKAWA, L. L., SCHWARTZ, R., PEREIRA, L., HENSLEIGH, P. A., PROBER, C. G. & ARVIN, A. M. 0988). Type-specific antibodies to herpes simplex virus type 2 (HSV-2) glycoprotein G in pregnant women, infants exposed to maternal HSV-2 infection at delivery and infants with neonatal herpes. Journal of Infectious Diseases 157, 164-I71. WHITLEY, R. J. (1985). Epidemiology of herpes simplex viruses. In The Herpesviruses, vol. 3, pp. 1~4. Edited by B. Roizman. New York: Plenum Press. (Received 5 December 1988)
Comparison of Western Blot (Immunoblot) and Glycoprotein G- Specific Immunodot Enzyme Assay for Detecting Antibodies to
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 1988, p. 662-667 0095-1137/88/040662-06$02.00/0 Copyright (O 1988, American Society for Microbiology Vol. 26, No. 4 Comparison of Western Blot (Immunoblot) and Glycoprotein
More information(Accepted 9 April 1986) SUMMARY
J. gen. Virol. (1986), 67, 1601-1612. Printed in Great Britain 1601 Key words: HSV-2/antibody response/recurrence/acyclovir Antibody Response, Recurrence Patterns and Subsequent Herpes Simplex Virus Type
More informationInaccuracy of Certain Commercial Enzyme Immunoassays in Diagnosing Genital Infections With Herpes Simplex Virus Types 1 or 2
Microbiology and Infectious Disease / INACCURACY OF CERTAIN HSV ELISA TESTS Inaccuracy of Certain Commercial Enzyme Immunoassays in Diagnosing Genital Infections With Herpes Simplex Virus Types 1 or 2
More informationHuman Herpes Simplex Virus Type 1 (HSV-1) IgM ELISA Kit
Human Herpes Simplex Virus Type 1 Catalog No: IRAPKT1412 (HSV-1) IgM ELISA Kit Lot No: SAMPLE INTENDED USE The HSV-1 IgM ELISA is intended for the detection of IgM antibodies to herpes simplex virus HSV-1.
More informationAntibodies by Enzyme-Linked Immunosorbent Assay
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1983, p. 287-291 0095-1137/83/080287-05$02.00/0 Vol. 18, No. 2 Determination of Herpes Simplex Virus Type-Specific Antibodies by Enzyme-Linked Immunosorbent Assay
More informationHerpes Simplex Virus Type 1 (HSV-1) IgM ELISA Kit Protocol
Herpes Simplex Virus Type 1 (HSV-1) IgM ELISA Kit Protocol (Cat. No.:EK-310-93) 330 Beach Road, Burlingame CA Tel: 650-558-8898 Fax: 650-558-1686 E-Mail: info@phoenixpeptide.com www.phoenixpeptide.com
More informationHerpes Simplex 1 IgM (HSV1 IgM)
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationThe cost-effectiveness of routine antenatal screening for maternal herpes simplex virus-1 and -2 antibodies Thung S F, Grobman W A
The cost-effectiveness of routine antenatal screening for maternal herpes simplex virus-1 and -2 antibodies Thung S F, Grobman W A Record Status This is a critical abstract of an economic evaluation that
More informationHerpes Simplex 1 IgM (HSV1 IgM)
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationReceived 19 September 2008/Returned for modification 4 November 2008/Accepted 13 November 2008
CLINICAL AND VACCINE IMMUNOLOGY, Jan. 2009, p. 55 60 Vol. 16, No. 1 1556-6811/09/$08.00 0 doi:10.1128/cvi.00351-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison of
More informationPreinfection Prophylaxis with Herpes Simplex Virus Glycoprotein Immunogens: Factors Influencing Efficacy
J. gen. Virol. (1989), 70, 3177-3185. Printed in Great Britain 3177 Key words: HSV/vaccines/guinea-pig Preinfection Prophylaxis with Herpes Simplex Virus Glycoprotein Immunogens: Factors Influencing Efficacy
More informationDetection of Immunoglobulin M Antibodies to Glycoprotein G-2 by Western Blot (Immunoblot) for Diagnosis of Initial
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 1993, p. 3157-3164 Vol. 31, No. 12 0095-1137/93/123157-08$02.00/0 Copyright C 1993, American Society for Microbiolog Detection of Immunoglobulin M Antibodies to Glycoprotein
More informationManual. Catalog number: This kit is for research use only, and is not for use in diagnostic procedures.
IGG Antibodies to Herpes Simplex Virus Type 1 (HSV-1) ELISA Quantitation Kit Manual Catalog number: 40-052-115033 For the quantitative determination of IGG Antibodies to Herpes Simplex Virus Type 1 (HSV-1)
More informationHSV-2 therapeutic vaccine program. Subunit vaccine candidates
HSV-2 therapeutic vaccine program Subunit vaccine candidates Our HSV-2 vaccine program Therapeutic subunit vaccine T-cell-based Aim: Best-in-class antigens by engineering Excellent standing (Sept 2017):
More information1 R21 AI A1 2 VMD HALFORD, W
1 R21 AI081072-01A1 2 VMD 1R21AI081072-01A1 ILLIAM RESUME AND SUMMARY OF DISCUSSION: The proposed study is to develop safe and effective live attenuated vaccines against herpes simplex virus 2 by using
More informationDiagnosis of Herpesvirus hominis Infections in a General Hospital Laboratory
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1975, p. 318-323 Copyright 1975 American Society for Microbiology Vol. 1, No. 3 Printed in U.S.A. Diagnosis of Herpesvirus hominis Infections in a General Hospital
More informationGenital Herpes in Guinea Pigs: Pathogenesis of the Primary Infection and Description of Recurrent Disease
THE JOURNAL OF INFECTIOUS DISEASES VOL. 146, NO.3. SEPTEMBER 1982 1982 by The University of Chicago. All rights reserved. 0022-1899/82/4603-0011$00.81 Genital Herpes in Guinea Pigs: Pathogenesis of the
More informationPerformance of commercial enzyme-linked immunosorbent assays (ELISA) for diagnosis of HSV-1 and HSV-2 infection in a clinical setting
Performance of commercial enzyme-linked immunosorbent assays (ELISA) for diagnosis of HSV-1 and HSV-2 infection in a clinical setting Elfriede Ampong Agyemang A thesis submitted in partial fulfillment
More informationDevelopment of Vaxfectin -formulated HSV-2 Plasmid DNA Vaccines for Prophylactic and Therapeutic Applications
Development of Vaxfectin -formulated HSV-2 Plasmid DNA Vaccines for Prophylactic and Therapeutic Applications Sean M. Sullivan, Ph.D. Executive Director Pharmaceutical Sciences 14 July 2011 - DNA Vaccines
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00836.x Performance of Focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations R. Ashley-Morrow
More informationHuman IgG Rubella ELISA Kit
Human IgG Rubella ELISA Kit Catalog No: IRAPKT2020 Lot No: SAMPLE INTENDED USE The Rubella IgG ELISA is intended for use in evaluating a patient s serologic status to the rubella virus infection. It is
More informationIgG Antibodies TO Rubella Virus ELISA Kit Protocol
IgG Antibodies TO Rubella Virus ELISA Kit Protocol (Cat. No.:EK-310-81) 330 Beach Road, Burlingame CA Tel: 650-558-8898 Fax: 650-558-1686 E-Mail: info@phoenixpeptide.com www.phoenixpeptide.com INTENDED
More informationSerological Analysis of Herpes Simplex Virus Types 1 and 2
INFECTION AND IMMUNITY, Jan. 1982, p. 363-367 Vol. 35, No. 1 19-9567/82/1363-5$2./ Serological Analysis of Herpes Simplex Virus Types 1 and 2 with Monoclonal Antibodies LENORE PEREIRA,* DALE V. DONDERO,
More informationPolypeptides after Primary and Recurrent Infection
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 1986, p. 725-730 0095-1137/86/040725-06$00/0 Copyright 1986, American Society for Microbiology Vol. 23, No. 4 Human Antibody Response to Herpes Simplex Virus-Specific
More informationPictArray ToRCH ELISA Kit
TORCH Instructions PictArray ToRCH ELISA Kit Instructions for testing human serum samples on PictArray ToRCH Panel consisting of Toxoplasma gondii, Rubella, Cytomegalovirus (CMV), Herpes Simplex Virus
More informationVirus-Specific Antibodies in Sera from Patients with Genital
INFECTiON AND IMMUNITY, Aug. 1982, p. 413-421 0019-9567/82/080413-09$02.00/0 Vol. 37, No. 2 Virus-Specific Antibodies in Sera from Patients with Genital Herpes Simplex Virus Infection HANS J. ZWEERINKt*
More informationGrouping of Feline Calicivirus Field Isolates Using Monoclonal Antibodies
SHORT REPORT Grouping of Feline Calicivirus Field Isolates Using Monoclonal Antibodies Tomoko TAJIMA, Erika NAKATA, Yukinobu TOHYAI1), Kazuyo YURI2), Hiromi KATAE2), and Takeshi MIKAMI3) Department of
More information21 st Century Herpes Solutions. William Halford, PhD RVx, Chief Science Officer
21 st Century Herpes Solutions William Halford, PhD RVx, Chief Science Officer Scope of Herpes Problem A major public health concern HSV-1 and/or HSV-2 HSV-2 infections ~100 million recurrent herpes severe
More informationPeptide Sequences of Glycoprotein G-2 Discriminate between Herpes Simplex Virus Type 2 (HSV-2) and HSV-1 Antibodies
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, May 1996, p. 265 269 Vol. 3, No. 3 1071-412X/96/$04.00 0 Copyright 1996, American Society for Microbiology Peptide Sequences of Glycoprotein G-2 Discriminate
More information21 st Century Herpes Solutions. William Halford, PhD RVx, Chief Science Officer
21 st Century Herpes Solutions William Halford, PhD RVx, Chief Science Officer Scope of Herpes Problem: by the numbers A major public health concern HSV-1 and/or HSV-2 HSV-2 infections ~100 million recurrent
More information21 Dec Dear Dr. Halford,
21 Dec 2016 Dear Dr. Halford, I am writing to you in regards to manuscript FVL 2016 0132 entitled "Genital herpes meets its match: a live HSV 2 ICP0 virus vaccine that succeeds where subunit vaccines have
More informationEase of Dual Priming Oligonucleotide Technology for the Genotyping of Herpes Simplex Virus.
Available online on www.ijtpr.com International Journal of Toxicological and Pharmacological Research 2013; 5(2): 42-46 Research Article ISSN: 0975-5160 Ease of Dual Priming Oligonucleotide Technology
More informationGuidance for Industry and FDA Staff. Class II Special Controls Guidance Document: Herpes Simplex Virus Types 1 and 2 Serological Assays
Reprinted from FDA s website by Guidance for Industry and FDA Staff Class II Special Controls Guidance Document: Herpes Simplex Virus Types 1 and 2 Serological Assays Document issued on: April 3, 2007
More informationReceived 26 April 2011/Accepted 27 July 2011
JOURNAL OF VIROLOGY, Oct. 2011, p. 10472 10486 Vol. 85, No. 20 0022-538X/11/$12.00 doi:10.1128/jvi.00849-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Immunization with a Vaccine
More informationInhibition of Herpesvirus hominis Replication by Human Interferon
INFECTION AND IMMUNITY, July 1975, p. 104-108 Copyright 0 1975 American Society for Microbiology Vol. 12, No. 1 Printed in U.S.A. Inhibition of Herpesvirus hominis Replication by Human Interferon LUCY
More information1 R01 AI VMD HALFORD, W
1 R01 AI104935-01 2 VMD 1R01AI104935-01 ILLIAM CRITIQUE 1: Significance: 5 Investigator(s): 2 Innovation: 5 Approach: 8 Environment: 2 Overall Impact: This application proposes to develop a recombinant
More informationType Specificity of Complement-Requiring and Immunoglobulin M Neutralizing Antibody in Initial Herpes Simplex Virus Infections of Humans
INFECTION AND IMMUNITY, OCt. 1975, p. 728-732 Copyright C) 1975 American Society for Microbiology Vol. 12, No. 14 Printed in U.S.A. Type Specificity of Complement-Requiring and Immunoglobulin M Neutralizing
More informationReceived 26 April 2011/Accepted 27 July 2011
JOURNAL OF VIROLOGY, Oct. 2011, p. 10472 10486 Vol. 85, No. 20 0022-538X/11/$12.00 doi:10.1128/jvi.00849-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Immunization with a Vaccine
More informationDeveloping T cell vaccines for HSV-2 Infection
Developing T cell vaccines for HSV-2 Infection Jessica Baker Flechtner, PhD World Vaccine Congress 24-26 March, 2014 Deep Pipeline of T Cell-Enabled Vaccine Candidates Discovery Pre-clinical Phase 1 Phase
More informationAntiviral Activity of Extracts from Marine Algaet
ANTIMICR0IAL AGENTS AND CHEMOTHERAPY, July 1978, p. 24-30 0066-4804/'7/0014-0024$02.00/0 Copyright 1978 American Society for Microbiology Vol. 14, No. 1 Printed in U.S.A. Antiviral Activity of Extracts
More informationA Live-Attenuated HSV-2 ICP0 2 Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit Vaccine
A Live-Attenuated HSV-2 ICP0 2 Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit Vaccine William P. Halford*, Ringo Püschel, Edward Gershburg, Andrew
More informationIGG Antibodies to Rubella Virus ELISA Quantitation Kit
IGG Antibodies to Rubella Virus ELISA Quantitation Kit Manual Catalog number: 40-052-115027 For the quantitative determination of IgG Antibodies to Rubella Virus in serum. This kit is for research use
More informationClinical Diagnostic Immunoblot. Storage: Store the entire experiment in the refrigerator. EXPERIMENT OBJECTIVES:
The Biotechnology Education Company 276 EDVO-Kit # Clinical Diagnostic Immunoblot Storage: Store the entire experiment in the refrigerator. EXPERIMENT OBJECTIVES: Dot-immunobinding Assay is a sensitive
More informationReceived 15 August 1997/Accepted 12 December 1997
JOURNAL OF VIROLOGY, Apr. 1998, p. 2760 2764 Vol. 72, No. 4 0022-538X/98/$04.00 0 Copyright 1998, American Society for Microbiology The Quantity of Latent Viral DNA Correlates with the Relative Rates at
More informationH erpes simplex virus type 2 (HSV-2) is the predominant
430 ORIGINAL ARTICLE An evidence based approach to testing for antibody to herpes simplex virus type 2 A J Copas, F M Cowan, A L Cunningham, A Mindel... See end of article for authors affiliations... Correspondence
More informationHELICA BIOSYSTEMS, INC. MOUSE C-REACTIVE PROTEIN QUANTITATION BY ELISA FOR RESEARCH USE ONLY
HELICA BIOSYSTEMS, INC. MOUSE C-REACTIVE PROTEIN QUANTITATION BY ELISA FOR RESEARCH USE ONLY INTENDED USE The Helica C-reactive protein assay is intended for the detection and quantification of mouse C-reactive
More informationRapid, Sensitive and Specific Lateral-Flow Immunochromatographic Pointof-Care. Device to Detect HSV-2 Specific Immunoglobulin G Antibodies in
CVI Accepts, published online ahead of print on 14 November 2007 Clin. Vaccine Immunol. doi:10.1128/cvi.00218-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationRapid, Sensitive and Specific Lateral-Flow Immunochromatographic Pointof-Care. Device to Detect HSV-2 Specific Immunoglobulin G Antibodies in
CVI Accepts, published online ahead of print on 14 November 2007 Clin. Vaccine Immunol. doi:10.1128/cvi.00218-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationSeroprevalence of Herpes Simplex Virus Types 1 and 2 United States,
MAJOR ARTICLE of Herpes Simplex Virus Types 1 and 2 United States, 1999 2010 Heather Bradley, 1 Lauri E. Markowitz, 1 Theda Gibson, 2 and Geraldine M. McQuillan 3 1 Centers for Disease Control and Prevention,
More informationab Anti-Herpes simplex virus Type 2 (HSV2) IgG Human ELISA Kit
ab108739 Anti-Herpes simplex virus Type 2 (HSV2) IgG Human ELISA Kit Instructions for Use For the qualitative measurement of IgG class antibodies against Herpes simplex virus Type 2 (HSV2) in Human serum
More informationToRCH IgG/IgM Assay Development
ToRCH IgG/IgM Assay Development www.meridianbioscience.com/lifescience ToRCH Overview ToRCH is an acronym for a group of infections that can cause significant birth defects and even fetal death. Meridian
More informationnamely type specificity and immunogenicity. This paper describes a simple procedure for
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 1979, p. 772-777 0095-1 137/79/12-0772/06$02.00/0 Vol. 10, No. 6 Isolation of the Major Herpes Simplex Virus Type 1 (HSV-1)- Specific Glycoprotein by Hydroxylapatite
More informationIgG Antibodies To Toxoplasma. Gondii ELISA Kit
IgG Antibodies To Toxoplasma Catalog No: IRAPKT1405 Gondii ELISA Kit Lot No: SAMPLE INTENDED USE The Toxoplasma IgG ELISA is intended for use in evaluating a patient s serologic status to Toxoplasma gondii
More information... Division of Laboratory Medicine, Department of Microbiology, Ullevaal University Hospital, Oslo, Norway 4
Journal of General Virology (1999), 80, 1789 1798. Printed in Great Britain... Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority
More informationParvovirus B19 IgG, IgM ELISA KIT
Parvovirus B19 IgG, IgM ELISA KIT Cat. No.:DEIA05717 Pkg.Size:96T Intended use The Parvovirus B19 Tests are enzyme immunoassays (EIA) for the quantitative determination of IgG and semi-quantitative determination
More informationHerpeSelect 1 and 2 Immunoblot IgG (K000238; Focus Diagnostics, Inc.)
I. GENERAL INFORMATION Submitter: Theranos, Inc. 1701 Page Mill Road Palo Alto, CA 94304 Phone: 650-838-9292 Fax: 650-838-9165 Contact Person: Brad Arington Associate Director, Regulatory Phone: 650-856-7304
More informationSee external label 2 C-8 C Σ=96 tests Cat # SHBG Cat #
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More information(Accepted 20 April 1989)
J. gen. Virol. (1989), 7, 2185-219. Printed in Great Britain 2185 Key words: RSV/vaccinia virus/antibody-mediated immune suppression Immunosuppression of the Antibody Response to Respiratory Syncytial
More informationHELICA BIOSYSTEMS, INC. HIGH SENSITIVITY HUMAN C-REACTIVE PROTEIN FOR RESEARCH USE ONLY (Not for in vitro diagnostic use)
INTENDED USE HELICA BIOSYSTEMS, INC. HIGH SENSITIVITY HUMAN C-REACTIVE PROTEIN FOR RESEARCH USE ONLY (Not for in vitro diagnostic use) The Helica C-reactive protein assay is intended for the detection
More informationTGFβ/TGFβR3 Signaling Pathways in Autoimmune Disease
Holifield 1 TGFβ/TGFβR3 Signaling Pathways in Autoimmune Disease Reggie Holifield Faculty mentor: Dr. Christine Sestero The University of Montevallo Dept. of Biology, Chemistry, and Mathematics Abstract
More informationTreatment of Experimental Herpesvirus Infections with Phosphonoformate and Some Comparisons with
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1978, p. 817-823 66-484/78/14-817$2./ Copyright X) 1978 American Society for Microbiology Vol. 14, No. 6 Printed in U.S.A. Treatment of Experimental Herpesvirus
More informationIn Search of the "Kissing Disease"
REVISED & UPDATED Edvo-Kit #274 In Search of the "Kissing Disease" Experiment Objective: 274 The objective of this experiment is to understand the experimental concepts and methodology involved with enzyme-linked
More informationThe Biotechnology Education Company. Quantitative ELISA. Storage: See Page 3 for specific storage instructions EXPERIMENT OBJECTIVE:
The Biotechnology Education Company Revised and Updated Quantitative ELISA Storage: See Page 3 for specific storage instructions EXPERIMENT OBJECTIVE: EDVO-Kit # 278 The objective of this experiment is
More informationHP EASE. Qualitative assay for IgG antibodies to Helicobacter pylori Product code GD21 (96 tests)
HP EASE Qualitative assay for IgG antibodies to Helicobacter pylori Product code GD21 (96 tests) For Research Use Only. Not For Use In Diagnostic Procedures. Updates from previous versions are non-critical
More informationAttribution: University of Michigan Medical School, Department of Microbiology and Immunology
Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution
More informationComparison of a commercial ELISA system with restriction endonuclease analysis for typing herpes
J Clin Pathol 1984;37:937-941 Comparison of a commercial ELISA system with restriction endonuclease analysis for typing herpes. ~ ~~~~~~~~. simplex virus KJ SMITH, CR ASHLEY,* JM DARVILLE, J HARBOUR,*
More informationPrevention of Genital Herpes Simplex Virus Type 1 and 2 Disease in Mice Immunized with a gd- Expressing Dominant-Negative Recombinant HSV-1
ORIGINAL ARTICLE Prevention of Genital Herpes Simplex Virus Type and Disease in Mice Immunized with a gd- Expressing Dominant-Negative Recombinant HSV- Richard Brans, Natali V. Akhrameyeva and Feng Yao
More informationLuteinizing Hormone ELISA kit
55R-IB19104 Luteinizing Hormone ELISA kit Enzyme Immunoassay for the determination of LH in human serum 1. Principle of the test: The LH ELISA kit is a solid phase direct sandwich method. The samples and
More informationADCC and HVEM: Lessons from an HSV-2 ΔgD vaccine. Clare Burn Laboratory of Betsy Herold and Laboratory of William R. Jacobs, Jr.
ADCC and HVEM: Lessons from an HSV-2 ΔgD vaccine Clare Burn Laboratory of Betsy Herold and Laboratory of William R. Jacobs, Jr. 1 Herpes Simplex Viruses Predominantly infect epithelial cells; establish
More informationBIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
More informationINFECTION RATES OF RESPIRATORY SYNCYTIAL VIRUS IN PEDIATRIC PATIENTS ATTENDING PHRA MONGKUTKLAO HOSPITAL, BANGKOK
INFECTION RATES OF RESPIRATORY SYNCYTIAL VIRUS IN PEDIATRIC PATIENTS ATTENDING PHRA MONGKUTKLAO HOSPITAL, BANGKOK SURANG TANTIVANICH, 0RALAK CHITYOTHIN and SAVANAT THARAVANIJ Department of Microbiology
More informationTechnics Used For The Demonstration of HHV-6 or HHV-7 Antigens in Tissues Immunopathology Laboratory, The University of Cologne (G.R.F.
1 Technics Used For The Demonstration of HHV-6 or HHV-7 Antigens in Tissues Immunopathology Laboratory, The University of Cologne (G.R.F. Krueger) Fixation: 4% Paraformaldehyde in 0.1 mol/l Buffer 4 g
More informationCHAPTER 24. Immunology
CHAPTER 24 Diagnostic i Microbiology and Immunology Growth-Dependent Diagnostic Methods Isolation of Pathogens from Clinical Specimens Proper sampling and culture of a suspected pathogen is the most reliable
More informationTechnical Reports LEISHMANIA RECOMBINANT ANTIGENS KMP11 AND K39
Technical Reports LEISHMANIA RECOMBINANT ANTIGENS KMP11 AND K39 The aim of the research presented in this technical report is to show the evaluation of the Leishmania recombinant antigens KMP-11 and K39
More informationHelicobacter pylori IgG CLIA Kit
Helicobacter pylori IgG CLIA Kit Catalog Number KA3644 96 assays Version: 01 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle
More informationAdenovirus Titration Kit
Adenovirus Titration Kit Catalog # LF-RK0001(1 kit) Immunostaining method for Quantitative Detection of Adenovirus For research use only Not for diagnostic or therapeutic procedures AbFrontier Science
More information7y-globulin) were obtained from Hyland Laboratories, Los Angeles, California. Prior to use, all sera NEUTRALIZATION OF AN INFECTIOUS HERPES SIMPLEX
NEUTRALIZATION OF AN INFECTIOUS HERPES SIMPLEX VIRUS-ANTIBODY COMPLEX BY ANTI-7t-GLOBULIN BY WARREN K. ASHE AND ABNER Louis NOTKINS LABORATORY OF MICROBIOLOGY, NATIONAL INSTITUTE OF DENTAL RESEARCH, NATIONAL
More informationIgG TrueBlot Protocol for Mouse, Rabbit or Goatderived Antibodies - For Research Use Only
IgG TrueBlot Protocol for Mouse, Rabbit or Goatderived Antibodies - For Research Use Only Introduction The IgG TrueBlot for mouse, rabbit, or goat-derived antibodies represents unique series of respective
More informationHerpes Simplex Virus 1 (HSV 1) IgG Human ELISA Kit
ab108737 Herpes Simplex Virus 1 (HSV 1) IgG Human ELISA Kit Instructions for Use For the qualitative determination of IgG class antibodies against Herpes Simplex Virus 1 (HSV 1) in Human serum or plasma
More informationSecretory Immunoglobulin A and Herpes Keratitis
INFECTION AND IMMuNrnr, Dec. 1970, p. 778-782 Copyright 1970 American Society for Microbiology Vol. 2, No. 6 Printed in U.S.A Secretory Immunoglobulin A and Herpes Keratitis Y. M. CENTIFANTO AND H. E.
More informationBIL 256 Cell and Molecular Biology Lab Spring, Development of the Immune System
BIL 256 Cell and Molecular Biology Lab Spring, 2007 Development of the Immune System Background Information I. Serum Proteins Blood is a remarkable tissue containing cellular elements (erythrocytes, leukocytes
More informationBean common mosaic virus (BCMV) ELISA Kit
Bean common mosaic virus (BCMV) ELISA Kit Cat.No: DEIAPV17 Lot. No. (See product label) Size 5000T Intended use The test can be used to detect BCMV in infected host plants. General Description Bean common
More informationSuperior efficacy of helicase-primase inhibitor BAY for herpes infection and latency in the guinea pig model of human genital herpes disease
Antiviral Chemistry & Chemotherapy 18:35 48 Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease Judith Baumeister
More informationInstruction Manual. Herpes 2 IgG ELISA
Instruction Manual Herpes 2 IgG ELISA Enzyme immunoassay based on microtiter plate for the detection and quantitative determination of human IgG antibodies against Herpes 2 in serum and plasma Cat. No.:
More informationThe Immunological Relationship between Canine Herpesvirus and Four Other Herpesviruses
J. gen. Virol. (1988), 69, 1601-1608. Printed in Great Britain 1601 Key words: CHV/herpesviruses/cross-reactivity The Immunological Relationship between Canine Herpesvirus and Four Other Herpesviruses
More informationPeliClass human IgG subclass ELISA kit Enzyme-linked immunosorbent assay
PeliClass human IgG subclass ELISA kit Enzyme-linked immunosorbent assay Catalog No: M1551 Size: six pre-coated 8-well strips for each of the four IgG subclasses Test description The PeliClass human subclass
More informationElectrophoresis and transfer
Electrophoresis and transfer Electrophoresis Cation = positively charged ion, it moves toward the cathode (-) Anion = negatively charged ion, it moves toward the anode (+) Amphoteric substance = can have
More informationHuman IgG Antigen ELISA Kit
Human IgG Antigen ELISA Kit Catalog No: IHUIGGKT Lot No: SAMPLE INTENDED USE This human immunoglobulin G antigen assay is intended for the quantitative determination of total human IgG antigen in serum,
More informationLaboratory Service Report
Laboratory Service Report 1-00-533-1710 SA0004515 SA0004515 Client SA0004515 0/14/2012 13:00 C702-DLP ROCHESTER 0/17/2012 14:39 eningoencephalitis Comp Panel, S REPORTED 0/16/2012 14:26 Lymphocytic Choriomeningitis
More informationASSAY OF TETANUS VACCINE (ADSORBED)
2.7.8. Assay of tetanus vaccine (adsorbed) 01/2005:20708 corrected 2.7.8. ASSAY OF TETANUS VACCINE (ADSORBED) The potency of tetanus vaccine is determined by administration of the vaccine to animals (guinea-pigs
More informationDeterminations of Antibody to Herpes Simplex Virus in Sera
JOURNAL OF CLINICAL MICROBIOLOGY, May 1982, p. 815-823 Vol. 15, No. 5 95-1137/82/5815-9$2./ Evaluation and Reporting of Enzyme Immunoassay Determinations of Antibody to Herpes Simplex Virus in Sera and
More informationHerpes Simplex Virus 1+2 (HSV)
Herpes Simplex Virus 1+2 (HSV) IgG - ELISA Enzyme immunoassay for the qualitative determination of IgG-class antibodies against HSV Type 1+2 in human serum or plasma Only for in-vitro diagnostic use GenWay
More informationPSEUDOMONAS-CF-IgG ELISA KIT
PSEUDOMONAS-CF-IgG ELISA KIT PSEUDOMONAS-CF-IgG ELISA Kit is for the quantitative measurement of the antibody level to P. aeruginosa in human serum samples. Application Chronic P. aeruginosa infection
More informationDetection of Herpes Simplex Virus DNA from Genital Lesions by In Situ Hybridization
JOURNAL OF CLINICAL MICROBIOLOGY, May 1988, p. 933-937 0095-1137/88/050933-05$02.00/0 Copyright 1988, American Society for Microbiology Vol. 26, No. 5 Detection of Herpes Simplex Virus DNA from Genital
More informationMRC5 Host Cell Proteins
MRC5 Host Cell Proteins Immunoenzymetric Assay for the Measurement of MRC5 Host Cell Proteins Catalog # F300 Intended Use This kit is intended for use in determining the presence of MRC5 host cell protein
More informationCyno Monkey IgG Antigen ELISA Kit
Cyno Monkey IgG Antigen ELISA Kit Catalog No: ICYIGGKT Lot No: SAMPLE INTENDED USE This cynomolgus macaque (Macaca fascicularis) monkey Immunoglobulin G (IgG) antigen assay is intended for the quantitative
More informationIgG1 (Mouse) ELISA Kit
IgG1 (Mouse) ELISA Kit Catalog Number KA1011 96 assays Version: 05 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the Assay... 3 General
More informationAN ELISA FOR THE DETECTION OF ANTIBODIES AGAINST NEWCASTLE DISEASE VIRUS IN AFRICAN VILLAGE POULTRY
AN ELISA FOR THE DETECTION OF ANTIBODIES AGAINST NEWCASTLE DISEASE VIRUS IN AFRICAN VILLAGE POULTRY J.G. BELL, M. LELENTA Animal Production Unit, Food and Agriculture International Atomic Energy Agency,
More informationHuman Toxoplasma gondii IgM ELISA Kit
Human Toxoplasma gondii IgM Catalog No: IRAPKT1400 ELISA Kit Lot No: SAMPLE INTENDED USE The Toxoplasma IgM ELISA is intended for use in the detection of IgM to Toxoplasma gondii in human serum. WARNINGS
More informationFor personal use only
ADMEDUS Ltd ABN 35 088 221 078 REGISTERED OFFICE: Level 1, 197 Adelaide Terrace Perth Western Australia 6000 PO Box 6879 East Perth Western Australia 6892 ASX ANNOUNCEMENT T +61 (0)8 9266 0100 F +61 (0)8
More information